Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 9/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694664 | 0.89 | TAAR1 (0.63) | CYP3A4LMNAACHETAAR1PARP1 | |
| SCHEMBL694663 | 0.89 | TAAR1 (0.63) | CYP3A4LMNAACHETAAR1PARP1 | |
| SCHEMBL810922 | 0.84 | ACHE (0.55) | ACHETAAR1MAOAMAOBMEN1 | |
| SCHEMBL9638163 | 0.83 | ACHE (0.50) | CYP3A4LMNAACHEPARP1BCHE | |
| SCHEMBL3156480 | 0.83 | SLC7A5 (0.59) | CYP3A4LMNA | |
| SCHEMBL5018939 | 0.82 | TAAR1 (0.53) | ACHETAAR1MEN1KMT2A | |
| SCHEMBL28554715 | 0.81 | ALOX15 (0.54) | ACHETAAR1MAOAMAOBKMT2A | |
| SCHEMBL4483616 | 0.81 | CYP3A4 (0.49) | CYP3A4LMNAACHETAAR1PARP1 | |
| SCHEMBL11280341 | 0.81 | CYP3A4 (0.49) | CYP3A4LMNAACHETAAR1PARP1 | |
| SCHEMBL2869059 | 0.81 | PPARG (0.46) | CYP3A4LMNAACHEPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220040193-A1 | FORMULATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS | BRIDGEBIO GENE THERAPY RESEARCH, INC. | 2022-02-10 | — | — | US | disclosed |
| EP-2249426-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEM CORP (JP) | 2019-07-10 | — | — | EP | disclosed |
| CN-105762402-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | 三菱化学株式会社 | 2016-07-13 | — | — | CN | disclosed |
| CN-103078137-B | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORP. (JP) | 2015-09-16 | — | — | CN | disclosed |
| US-9083058-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9034850-B2 | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-05-19 | — | — | US | disclosed |
| CN-104600360-A | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEM CORP | 2015-05-06 | — | — | CN | disclosed |
| US-8916298-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8889302-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-11-18 | — | — | US | disclosed |
| US-8846254-B2 | — | — | 2014-09-30 | — | — | US | disclosed |
| US-20140134481-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-05-15 | — | — | US | disclosed |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | SK CHEMICALS CO. LTD. (KR) | 2013-05-30 | — | — | US | disclosed |
| CN-103078137-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | MITSUBISHI CHEM CORP | 2013-05-01 | — | — | CN | disclosed |
| US-20120308883-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120219854-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20110123871-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMCIAL (JP) | 2011-05-26 | — | — | US | disclosed |
| CN-101960662-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | MITSUBISHI CHEM CORP | 2011-01-26 | — | — | CN | disclosed |
| EP-2249426-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | Mitsubishi Chemical Corporation (JP) | 2010-11-10 | — | — | EP | disclosed |
| CN-1087337-A | The quinolin-2-ylmethoxy phenylacetic acid derivatives that replaces | BAYER AG (DE) | 1994-06-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | GNRHR, GHRHR, LHCGR | CYP3A4 1342/4885LMNA 3089/4885ACHE 2272/4885 |
| US-20220040193-A1 | FORMULATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3R1, PIK3C3, PIK3R2 | CYP3A4 4161/4885LMNA 1412/4885ACHE 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.